Serum heat shock protein 27 immunoglobulin G (IgG) antibody titers (anti-HSP27) and high-sensitivity C-reactive protein (hsCRP) concentrations were measured in samples from 168 patients in the first 24 hours after the onset of stroke and 80 age-and sex-matched control participants. In patients with stroke, median serum anti-HSP27 titer was significantly higher than that of the control group (0.18 [0.14-0.28] vs 0.08 [0.04-0.12], P < .001). Median serum hsCRP concentration was also significantly higher in patients compared with the control group (11.43 [8.07-13.53] vs 3.23 [1.66-6.24], P < .001). Serum anti-HSP27 and hsCRP concentrations did not differ significantly among patients with different stroke types. Neither serum anti-HSP27 nor hsCRP levels predicted 6-month prognosis in the patients with stroke. We conclude that serum anti-HSP27 titers and hsCRP concentrations are elevated in patients with stroke but do not distinguish between stroke types or predict 6-month prognosis.
Bogousslavsky J., Van MG, Regli F.The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke. 1988;19(9):1083-1092.
2.
Curb JD, Abbott RD, Rodriguez BL, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation. 2003;107(15):2016-2020.
3.
Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke. 2001;32(11): 2575-2579.
4.
Canova CR, Courtin C., Reinhart WHC-reactive protein (CRP) in cerebrovascular events. Atherosclerosis . 1999;147(1):49-53.
5.
Di NM, Papa F., Bocola V.C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke. 2001;32(4):917-924.
6.
Emsley HC, Smith CJ, Gavin CM, et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol. 2003;139(1-2):93-101.
7.
Winbeck K., Poppert H., Etgen T., et al. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke. 2002;33(10):2459-2464.
8.
Smith CJ, Emsley HC, Gavin CM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004;4:2.
9.
Iyigun I., Bakirci Y.Plasma concentrations of C-reactive protein and fibrinogen in ischaemic stroke . J Int Med Res. 2002;30(6): 591-596.
10.
Badin RA, Lythgoe MF, van der WL, et al. Neuroprotective effects of virally delivered HSPs in experimental stroke. J Cereb Blood Flow Metab.2006;26(3):371-381.
11.
Rajdev S., Hara K., Kokubo Y., et al. Mice overexpressing rat heat shock protein 70 are protected against cerebral infarction. Ann Neurol. 2000 ;47(6):782-791.
12.
Badin RA, Modo M., Cheetham M., et al. Protective effect of post-ischaemic viral delivery of heat shock proteins in vivo. J Cereb Blood Flow Metab.2009;29(2):254-263.
13.
Latchman DSProtective effect of heat shock proteins in the nervous system. Curr Neurovasc Res. 2004 ;1(1):21-27.
14.
Gromadzka G. , Zielinska J., Ryglewicz D., et al. Elevated levels of anti-heat shock protein antibodies in patients with cerebral ischemia. Cerebrovasc Dis. 2001;12(3):235-239.
15.
Staub HL, Norman GL, Crowther T., et al. Antibodies to the atherosclerotic plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia. Arq Neuropsiquiatr. 2003;61(3b):757-763.
16.
Kazemi-Bajestani SM, Ghayour-Mobarhan M., Ebrahimi M., et al. C-reactive protein associated with coronary artery disease in Iranian patients with angiographically defined coronary artery disease. Clin Lab. 2007;53(1-2):49-56.
17.
Ghayour-Mobarhan M., Sahebkar A., Parizadeh SM, et al. Antibody titres to heat shock protein 27 are elevated in patients with acute coronary syndrome. Int J Exp Pathol. 2008;89(3): 209-215.
18.
Azarpazhooh MR, Etemadi MM, Donnan GA, et al. Excessive incidence of stroke in Iran. Evidence from the Mashhad Stroke Incidence Study (MSIS): a population-based study of stroke in the Middle East. Stroke. 2010;41(1):e3-e10.
19.
Terruzzi A. , Valente L., Mariani R., Moschini L., Camerlingo M.C-reactive protein and aetiological subtypes of cerebral infarction. Neurol Sci. 2008;29(4):245-249.
20.
Audebert HJ , Rott MM, Eck T., Haberl RLSystemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis. Stroke. 2004;35(9):2128-2133.
21.
Kramer J., Harcos P., Prohaszka Z., et al. Frequencies of certain complement protein alleles and serum levels of anti-heat-shock protein antibodies in cerebrovascular diseases. Stroke. 2000; 31(11):2648-2652.
22.
Mantle R., Singh B., Hachinski V.Do serum antibodies to heat-shock protein 65 relate to age or stroke? Lancet. 1995; 346(8991-8992):1715.
23.
Eikelboom JW , Hankey GJ, Baker RI, et al. C-reactive protein in ischemic stroke and its etiologic subtypes. J Stroke Cerebrovasc Dis. 2003;12(2):74-81.
24.
Ladenvall C. , Jood K., Blomstrand C., et al. Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke . 2006;37(8):2018-2023.
25.
Masotti L., Ceccarelli E., Forconi S., et al. Prognostic role of C-reactive protein in very old patients with acute ischaemic stroke. J Intern Med. 2005 ;258(2):145-152.
26.
Ridker PMHigh-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation . 2001;103(13):1813-1818.
27.
Anzai T., Yoshikawa T., Shiraki H., et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 1997;96(3): 778-784.
28.
Di NM, Schwaninger M., Cappelli R., et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36(6):1316-1329.
29.
Ridker PM, Cushman M., Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 ;336(14):973-979.
30.
Veres A., Fust G., Smieja M., et al. Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events. Circulation. 2002;106(22):2775-2780.
31.
Xu Q., Kiechl S., Mayr M., et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study . Circulation. 1999; 100(11):1169-1174.
